Jyong Biotech (NASDAQ:MENS) Trading Down 6.1% - Here's Why

Key Points

• Jyong Biotech Ltd. (NASDAQ:MENS) experienced a 6.1% stock decline, trading at $58.23 during mid-day on Wednesday, with trading volume significantly down to 31,378 shares compared to an average of 209,220.
• Analysts have upgraded Jyong Biotech to a "hold" rating, indicating a more stable outlook for the company's stock.
• The stock's fifty-day moving average price stands at $40.00, revealing a notable difference from its recent trading levels.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares fell 6.1% during mid-day trading on Wednesday . The stock traded as low as $58.23 and last traded at $58.23. 31,378 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 209,220 shares. The stock had previously closed at $62.00.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Jyong Biotech to a "hold" rating in a research note on Monday, June 30th.

Jyong Biotech Price Performance

The stock's fifty day moving average price is $40.00.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.